Peter Hoagland, MD
Advanced Heart Failure and Transplant Cardiology · San Diego, CANPI 1629059779
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,955 of the $9,393 with a category attached, or 63.4%. 39 manufacturers reported payments, led by Boehringer Ingelheim at 31.4% of the total. Reporting peaked in 2019 at $3,850 and has fallen 91.4% since, to $333 in 2025. That places this record below the midpoint for advanced heart failure and transplant cardiology clinicians in CA, where the typical reported total is $9,367.
Across 360 payments — averaging $26.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$3K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$1K
- AstraZeneca$1K
- Novartis$610
- Abbott$610
- Merck$301
- plus $3K from 33 others
Across 25 payments — averaging $9297.34 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Accriva Diagnostics Inc.$170K
- Novartis$23K
- Boston Scientific$19K
- Amgen$14K
- Amarin Pharma, Inc.$6K
What the payments were for
- Consulting fees$4355%
- Speaking & faculty fees$2,89531%
- Food & beverage$5,95563%
- Education$1081%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 10 | $2,953 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 74 | $1,166 |
| AstraZeneca | 29 | $1,096 |
| Novartis | 41 | $610 |
| Abbott | 19 | $610 |
| Merck | 13 | $301 |
| Pfizer | 35 | $249 |
| Amarin Pharma, Inc. | 4 | $179 |
| Johnson & Johnson | 12 | $179 |
| Medtronic(2 entities) | 4 | $178 |
| Heartflow, Inc. | 6 | $168 |
| Actelion Pharmaceuticals US, Inc. | 30 | $157 |
| Amgen | 6 | $148 |
| Kowa Pharmaceuticals America, Inc. | 8 | $146 |
| Alnylam Pharmaceuticals Inc. | 6 | $113 |
| Esperion Therapeutics, Inc. | 7 | $108 |
| Novo Nordisk | 6 | $107 |
| Regeneron Healthcare Solutions, Inc. | 6 | $101 |
| Bayer | 6 | $89 |
| E.r. Squibb & Sons, L.L.C. | 5 | $88 |
| Boston Scientific | 5 | $79 |
| Cvrx, Inc. | 2 | $72 |
| Irhythm Technologies, Inc. | 3 | $61 |
| Chiesi USA, Inc. | 3 | $52 |
| United Therapeutics Corporation | 2 | $44 |
| Daiichi Sankyo Inc. | 2 | $42 |
| Scpharmaceuticals Inc. | 2 | $39 |
| Cathworks, Inc. | 1 | $35 |
| Akcea Therapeutics, Inc. | 1 | $26 |
| Astellas Pharma US Inc | 1 | $23 |
| Sanofi-aventis U.S. LLC | 2 | $23 |
| Tactile Systems Technology Inc | 2 | $23 |
| Biosense Webster, Inc. | 1 | $23 |
| Abiomed | 1 | $22 |
| Nuwellis, Inc. | 1 | $21 |
| Otsuka America Pharmaceutical, Inc. | 1 | $17 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $17 |
| Arbor Pharmaceuticals, Inc. | 1 | $13 |
| Bardy Diagnostics, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PRADAXA$2,830
- FARXIGA$500
- CardioMEMS HF System$140
- Xience Sierra Coronary Stent System$131
- Vascepa$123
How this compares
$9,393 in reported general payments places this provider in the 50th percentile of 111 advanced heart failure and transplant cardiology providers in California.
See all advanced heart failure and transplant cardiology providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 278 | $394,719 |
| EntrestoSacubitril/Valsartan | 120 | $194,373 |
| XareltoRivaroxaban | 124 | $185,518 |
| JardianceEmpagliflozin | 73 | $97,507 |
| FarxigaDapagliflozin Propanediol | 72 | $89,902 |
| VascepaIcosapent Ethyl | 62 | $38,910 |
| Repatha SureclickEvolocumab | 33 | $37,091 |
| Repatha PushtronexEvolocumab | 19 | $22,451 |
| Praluent PenAlirocumab | 14 | $18,802 |
| NexlizetBempedoic Acid/Ezetimibe | 16 | $15,174 |
| Ezetimibe | 223 | $9,522 |
| Dofetilide | 18 | $7,948 |
| Valsartan | 200 | $7,387 |
| Atorvastatin Calcium | 409 | $4,394 |
| Rosuvastatin Calcium | 171 | $4,096 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $249 | $394,719278 claims |
| NovartisEntresto | $610 | $194,373120 claims |
| Johnson & JohnsonXarelto | $179 | $185,518124 claims |
| Boehringer IngelheimJardiance | $2,953 | $97,50773 claims |
| AstraZenecaFarxiga | $1,096 | $89,90272 claims |
| Esperion Therapeutics, Inc.Nexlizet | $108 | $15,17416 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 111 advanced heart failure and transplant cardiology providers in California.
Other advanced heart failure and transplant cardiology in San Diego
- Hirsch MehtaSan Diego$494K
- Marcus UreySan Diego$341K
- Barry GreenbergSan Diego$270K
- Brian JaskiSan Diego$235K
- Ajay SrivastavaSan Diego$203K
- Jorge Silva EncisoSan Diego$164K
- Burhan MohamedaliSan Diego$154K
- Hao TranSan Diego$147K
- Justin ParizoSan Diego$24K
- Eric AdlerSan Diego$24K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.